Counting the Votes: Democrats Consider Their Public Options On Health Reform and Reconciliation
This article was originally published in RPM Report
Democrats always feared having the health care reform debate carrying over past August. Now it’s October. Media coverage of chaotic town hall meetings, intra-party disputes, and a united Republican opposition show how prescient the Democrats were to worry about debate after the summer holidays. Democrats are now starting to consider how they’ll vote on a fi nal bill. Here’s what it could look like if the legislation goes through the Congressional shortcut of budget reconciliation and includes a public plan.
You may also be interested in...
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach.
The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.